Make MENAFN My Home Page
 
  Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Dubai's Hikma signs agreement with Boehringer on Bedford acquisition  Join our daily free Newsletter

MENAFN - 01/06/2014
No. of Ratings : 0
Add to Mixx!


(MENAFN) Nasdaq Dubai-listed Hikma Pharmaceuticals and Ben Venue Laboratories, a member of the Boehringer Ingelheim Group of Companies, have signed an agreement to acquire Bedford Laboratories, its US generic injectables business, according to the Emirates 24/7.

The company has already paid USD225 million in upfront cash out of the total USD300 million, while the remaining USD75 million will be paid over the coming five ears based on the achievement of the company's performance.


Under the agreement, Hikma is acquiring Bedford's assets, which is a generic injectables company with the third largest portfolio of generic injectable products in the US.

The assets will include a large product portfolio, intellectual property rights, contracts for products marketed under license, and a number of employees across key business functions.

 
 


MENAFN




Loading, Please wait....


 





Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

Search News
Market Indices
Quotes & Charts

Global Indices
Arab Indices

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Economic Calendar
Financial Glossary


Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help